Contemporary options and future perspectives: three examples highlighting the challenges in testicular cancer imaging

Gamal Anton Wakileh1 · Christian Ruf2 · Axel Heidenreich3 · Klaus-Peter Dieckmann4 · Catharina Lisson5 · Vikas Prasad6,7 · Christian Bolenz1,7 · Friedemann Zengerling1,7

Received: 11 July 2021 / Accepted: 4 October 2021 / Published online: 15 November 2021
© The Author(s) 2021

Abstract

Purpose One of the main issues in testicular germ cell tumors (TGCTs) management is to reduce the necessary amount of treatment to achieve cure. Excess treatment burden may arise from late diagnosis of the primary as well as from false positive or negative staging results. Correct imaging is of paramount importance for successful management of TGCT. The aim of this review is to point out the current state of the art as well as innovative developments in TGCT imaging on the basis of three common challenging clinical situations.

Methods A selective literature search was performed in PubMed, Medline as well as in recent conference proceedings.

Results Regarding small testicular lesions, recent studies using elastography, contrast-enhanced ultrasound or magnetic resonance imaging (MRI) showed promising data for differentiation between benign and malignant histology. For borderline enlarged lymph nodes FDG-PET-CT performance is unsatisfactory, promising new techniques as lymphotropic nanoparticle-enhanced MRI is the subject of research in this field. Regarding the assessment of postchemotherapeutic residual masses, the use of conventional computerized tomography (CT) together with serum tumor markers is still the standard of care. To avoid overtreatment in this setting, new imaging modalities like diffusion-weighted MRI and radiomics are currently under investigation. For follow-up of clinical stage I TGCTs, the use of MRI is non-inferior to CT while omitting radiation exposure.

Conclusion Further efforts should be made to refine imaging for TGCT patients, which is of high relevance for the guidance of treatment decisions as well as the associated treatment burdens and oncological outcomes.

Keywords Testicular cancer · Germ cell tumors · Seminoma · Non-seminoma · Imaging · Small testicular masses · Staging

Introduction

Testicular germ cell tumors (TGCTs) represent the most common malignancy among young men aged 15–40 years [1, 2]. Clinically, TGCTs are categorized into seminomas and non-seminomas with relatively equal proportions of 50%–60% for seminomas and 40%–50% for non-seminomas [2, 3]. Among the entire histologic spectrum of testicular neoplasms, TGCTs comprise of 90%–95% of the cases [4, 5] and the remainder comprise of a great variety non-germ
cell tumors, for example sex-cord stromal tumors (Leydig cell tumors, Sertoli cell tumors), lymphomas or metastatic lesions arising from other solid malignancies [4].

Clinical diagnosis of TGCTs relies on physical examination, testicular ultrasound and determination of specific tumor markers such as alpha fetoprotein (AFP), beta-hCG (β-hCG) and lactate dehydrogenase (LDH) [4, 6]. At initial presentation, the tumor is confined to the testis in 68%–75% of the cases (clinical Stage I), regional lymph nodes metastasis in 15%–20% of the cases (clinical Stage II) and distant metastasis in 5%–12% of the cases (clinical Stage III) [6–9].

Currently, computed tomography (CT) is the standard imaging modality for initial staging, recommended by national and international TGCT treatment guidelines [5, 10–12].

Due to the young age of the patient and annual CT imaging after initial therapy, the iatrogenic radiation exposure is a major concern. Depending on the clinical stage, an average of two CT scans per year are performed during a median follow-up time of 4–6 years [13]. This leads to a cumulative increase in radiation exposure over time, which further increases the lifetime risk of second malignancies up to 1.9%–2.6% [13, 14].

In this review, we aim to point out the present best standard as well as future options of improving TGCT management on the basis of three particular clinical scenarios.

**Methods**

A selective literature search was performed in PUBMED, Medline as well as in different conference proceedings (ASCO, ESMO, EAU meeting).

**Results**

**The ambiguous primary–small testicular lesions**

Clinically, the suspicion of a testicular tumor is raised by a painless increase in size of the testis or a hard nodule on palpation. According to current guidelines, scrotal ultrasound is required to confirm the clinical diagnosis and to aid decision making for surgery. Grayscale scrotal sonography is performed with B-mode high frequency (≥ 10 MHz) ultrasound probes providing high resolution images of the scrotal contents. Application of color-coded duplex sonography is used to assess the vascularization of intratesticular masses.

On B-mode ultrasound, seminomas present mostly hypoechoic, sometimes lobulated and tend to be homogeneous compared to normal testicular tissue [15, 16]. In contrast, most non-seminomas are rather inhomogeneous and show sometimes cystic structures and/or calcifications, which can be explained by more common tumor necrosis, mixed histologies and teratoma components [15, 16]. Despite some distinct differences between seminomas and non-seminomas on ultrasound, no clear differentiation can be made preoperatively.

The widespread use of ultrasound, particularly in the diagnostic workup of infertile men has brought about an increase of incidentally detected small testicular masses [17]. A small testicular mass is usually characterized as a lesion smaller than < 1 cm to < 2 cm, although definitions are conflicting among studies [5, 18, 19]. Recent investigations revealed that about 66%–75% of small masses are benign, mostly consisting of Leydig cell tumors, and other non-germ cell neoplasms that would be overtreated by orchiectomy [20, 21].

To improve diagnostic accuracy, new ultrasound techniques such as shear wave elastography (SWE) and contrast-enhanced ultrasound (CEUS) have been investigated. Recent studies showed that in SWE an increased stiffness of the suspicious tissue compared to normal testicular tissue can be associated with malignancy [22, 23]. Contrast-enhanced ultrasound (CEUS) versus unenhanced B-mode ultrasound was investigated for the detection of small, nonpalpable testicular tumors < 1.5 cm and for the differentiation between benign and malignant. This technique employs contrast medium that is administered intravenously in the form of “micro gas bubbles”. The oscillation of these microbubbles is detected on ultrasound and allows differentiation between various tissues by specific flooding characteristics (“wash in” and “wash out”) within the tissue. The investigators were able to show that malignant testicular tumors have an increased blood flow and contrast uptake compared to normal testicular parenchyma with a high sensitivity and specificity of 81.6% and 90%. The results are limited by the dependence of the qualitative analysis on the place and region of interest (ROI) and the experience of the observer as well as the lack of external validation of the study results [19]. However, due to the promising results as well as the absence of radiation exposure, this technique can be used as a supportive examination, especially in testicular lesions < 1.5 cm. It was shown that Leydig cell tumors had a faster wash in and prolonged wash out compared to seminomas, which can be used for differential diagnosis. According to the ESUMB guidelines, CEUS ultrasound can be used to visualize and differentiate between vascularized and non-vascularized testicular lesions to help exclude malignancy [24] (Fig. 1).

Scrotal MRI has been investigated as another technique to improve the characterization of equivocal testicular masses [25]. New analytic methods from the MRI sequences, such as histogram, radiomics and diffusion-weighted imaging (DWI) have shown good results in distinguishing between seminomas and non-seminomas [26–30]. Feliciani et al. were able to determine the histology of testicular tumors...
with an overall accuracy of 86%–89% via MRI radiomics signature [29]. The results are limited by the small number of the assessed lesions \((n = 44)\) as well as the lack of external validation and should therefore be considered rather as a proof of concept. Another retrospective work on 41 patients with histologically confirmed germ cell tumors revealed a very good differentiation between seminomas and non-seminomas via DWI-MRI [30]. As overall evidence for MRI to differentiate between malignant and benign testicular tumors is sparse, it is so far only recommended as an auxiliary examination method in ambiguous cases of small intratesticular lesions, doubtful paratesticular masses or in preparation for organ-preserving surgery [5, 25].

In summary, the new ultrasound and MRI techniques mentioned above are able to discriminate benign and malignant testicular lesions with an accuracy not greater than 90%. Therefore, due to the current insufficient data, surgical exploration with subsequent histologic examination is still indispensable [5]. In this context, intraoperative frozen section examination (FSE) is a valuable option during testis surgery and is mandatory in synchronous bilateral tumors, metachronous contralateral tumors or in patients with a solitary testis according to the EAU guidelines [5].

**Detection of retroperitoneal lymph node involvement during initial staging and follow-up of stage I TGCTs**

Correct staging and risk stratification is of paramount importance for the management of TGCT patients.

Computed tomography of the chest and abdomen was developed in the early 1980’s and is still the gold standard for staging in TGCT. A recent review by Pierorazio et al. reported contrast-enhanced abdominal CT to have an average sensitivity and specificity of 66.7% (37%–100%) and 95.2% (58%–100%), respectively. The median positive predictive value, negative predictive value and accuracy were shown to be 87.4% (60%–100%), 73.4% (67%–100%) and 83% (71%–100%), respectively [31].

Sensitivity and specificity values for CT are determined by the cut-off applied for lymph node size. Thus, a cut-off for lymph nodes \(\geq 10 \text{ mm}\) involves a sensitivity of 37% and a specificity of 100% compared to 93% and 58% for a cut-off \(\geq 4 \text{ mm}\) [31]. A number of investigators tried to improve sensitivity by lowering the threshold for lymph node diameter to be considered pathological. Traditionally, lymph nodes with a short axis diameter of \(\geq 10 \text{ mm}\) are considered to be pathological [32]. The Swedish Norwegian Testicular Cancer group (SWENOTENCA) defines enlarged lymph nodes larger than 10 mm in long diameter and larger than 8 mm in
short diameter, above the aortic bifurcation to be pathologi-
cal [33]. For non-seminomas, Hilton et al. recommend even
lymph nodes equal or larger than 4 mm, especially located
anterior to the mid portion of the aorta, to be considered
suspicious [34]. In their retrospective analysis, preoperative
CT images were correlated with histopathologic results of
primary retroperitoneal lymphadenectomy in 70 patients and
for a 4 mm threshold a sensitivity of 93% and specificity of
58% was reported [34].

However, the repetitive use of CT, as the gold standard
in follow-up care, exposes patients to increased diagnostic
radiation. Depending on the clinical stage, TGCT patients
receive up to 16 CT scans in a period of 5 years, leading
to an increase in the lifetime risk for the development of a
second malignancy that ranges between 1.9% and 2.6% [14].
To avoid unnecessary radiation exposure, studies have been
conducted comparing MRI with CT in follow-up.

For the assessment of retroperitoneal lymph nodes,
abdominal MRI in comparison to abdominal CT yields simi-
lar results with a sensitivity between 78% and 96% [35]. The
recently published TRISST study, a phase III non-inferior-
ity trial compared abdominal MRI with abdominal CT for
detection of early recurrence in patients with clinical stage I
seminoma [36]. The study consisted of two study compari-
sons: 3 MRI scans vs. 3 CT scans as well as 7 MRI scans vs.
7 CT scans. Whereas the proportion of relapses in advanced
stages (define as clinical stage ≥ 2C) where similar in both
7 CT scans. Whereas the proportion of relapses in advanced
stages (define as clinical stage ≥ 2C) where similar in both
comparisons between CT and MRI, the 3-scan regimen
resulted in a slightly but not significantly higher proportion
of relapses in advanced stages (define as clinical stage ≥ 2C)
compared to the 7 scan scheme (2.8% vs. 0.3%).

A prospective study on 50 patients with primary TGCTs
(seminoma and non-seminoma) investigated the accuracy of
DWI-MRI compared to CT for imaging retroperitoneal
lymph node metastases. All patients received CT and a
subsequent MRI. 30 patients were clinical stage I, 17 were
stage II, two were stage III, and one was stage IV. The study
showed a sensitivity of 98% for MRI in the detection of ret-
roperitoneal lymph nodes and a non-inferiority compared to
CT, but the results are limited by the design, which did not
allow the analysis of false-positive results in MRI, due to the
low number of control patients [37].

Another large retrospective cohort study investigated
abdominal DWI-MRI in the follow-up of clinical stage I
TGCTs to detect relapse. A total of 759 patients were
included during 2010–2018. Of these, 69% had seminoma
(n = 524) and 31% had non-seminoma (n = 235). DWI-MRI
showed a sensitivity of 93.8%, specificity of 97.4%, nega-
tive predictive value of 99.7%, positive predictive value of
59.9% and an accuracy of 97.3% in the detection of relapse.
With a lymph node cut-off of ≥ 10 mm, the specificity even
increased to 100% [38]. For an overview of the performance
characteristics of CT and MRT for lymph node imaging
according to the literature, see Table S1 in the supplemen-
tal material.

Despite its encouraging results, MRI has not yet gained
the status of a standard procedure due to limited evidence
from further studies, higher costs, longer examination time
and the availability of experienced radiologists to inter-
pret the images [31, 32, 35]. From the perspective of the
current guidelines, MRI is already recommended in the
follow-up of TGCT by the ESMO guideline as well as the
German TGCT guideline [10, 11]. Further advances in
MRI are awaited from technological innovations, that
allow improved differentiation of image sequences such as
T1, T2, DWI and as well as the reduction of examination
time and costs [38].

Driven by the relatively high false negative rate of tradi-
tional imaging methods for clinical stage I, new imag-
ing methods have been investigated during the last decade.
Lymphotropic nanoparticle-enhanced MRI (LNMI) has
been tested for TGCT staging [40]. LNMI is a type of
special contrast-enhanced MRI, where ultrasmall superpar-
amagnetic iron oxide (USPIO) such as ferumoxtran-10 is
administered intravenously. In a pilot study by Harisinghani,
this technique was investigated in 18 patients with stage I
testicular cancer. MRI was performed 24 h before intrave-
nous administration and 24 h thereafter. As a control, lymph
nodes were obtained per biopsy or surgery and underwent
histopathologic examination. The results are very promis-
ing as LNMI had a sensitivity for malignant lymph node
involvement of 88.2%, a specificity of 92% and an accuracy
of 90.4%. In comparison, the sensitivity of the established
size criteria for the detection of malignant nodules on MRI
only was 70.5%, the specificity was 68% and the accuracy
was 69% [40]. However, the results of the study are limited
due to the very small sample size and need confirmation in
larger controlled studies.

Currently, whole-body diffusion-weighted MRI imaging,
a new enhanced MRI imaging method, is investigated for
stage II-III testicular cancer within the prospective TENY
study (NCT03436901), after a prospective feasibility study
of Mosavi et al., evaluating this technique for follow-up, has
reported encouraging results [41, 42].

A series of studies investigated the value of FDG-PET-CT
for initial staging. A recently published review by Pierorazio
et al. found for initial staging an overall mean sensitivity,
specificity, positive predictive value, negative predictive
value, and accuracy for PET-CT of 72% (0%–100%), 90% (0%–100%), 94% (80%–100%), 81% (0%–100%) and 86%
(62.5%–100%), respectively [31]. In two studies, focusing on
primary retroperitoneal staging of seminomas, the applica-
tion of a FDG-PET-CT resulted in even better diagnostic
values up to 100%, but it did not have a relevant impact on
clinical management of these patients [43, 44]. In an older
prospective series of 37 stage I–II patients, who underwent
retroperitoneal lymph node dissection, FDG-PET-CT failed to identify vital cancer with a diameter less than 5 mm and was therefore judged insufficient to improve staging for early disease stages [45]. In conclusion, because of its limited sensitivity for small metastatic lesions and its excess radiation, the use of FDG-PET-CT is not justified for routine staging or restaging of stage I TGCT patients. However, it can be recommended as an additional tool for inconclusive CT findings [39, 46] (Fig. 2).

Fig. 2 Abdominal and thoracic FDG-PET-CT of an ambiguous retroperitoneal lymph node. a: abdominal CT-Scan. Figure b–d: FGD-PET-CT scan of abdomen/thorax/neck and head with an enlarged interaortocaval lymph node (green arrow) and intense FDG uptake in a patient with right sided seminoma and slightly increased lymph node after orchiectomy (Pictures from “Testicular cancer: Diagnosis and Initial Management”, Springer-Verlag)

The postchemotherapy residual mass

Approximately 30%–40% of metastatic TGCTs exhibit residual tumors after first-line chemotherapy that consist of necrosis/fibrosis, mature teratomas or viable carcinoma cells in around 40%–50%, 20%–40% and 10–20% of cases [47, 48]. Although PET-CT is currently not of significant value in initial staging, it is recommended in seminomas with residual tumors > 3 cm after first-line chemotherapy or radiotherapy to detect possibly viable tumor cells and to guide further management [5, 47]. The retrospective validation of the SEMPET trial demonstrated for PET-CT after platinum-based chemotherapy in seminoma an overall sensitivity, specificity, negative predictive value, positive predictive value, and accuracy of 67%, 82%, 93%, 42%, and 80%, respectively [49]. The excellent NPV is of particular value since a negative FDG-PET-CT scan allows to keep seminoma patients on follow-up. When FDG-PET-CT was performed after a minimum of 6 weeks after completion of chemotherapy, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy markedly improved to 82%, 90%, 95%, 69%, and 88%, respectively [49]. However, a recent study challenged these previous findings. Cathomas et al. demonstrated in their retrospective study following 95 patients with metastatic seminoma and residual tumors of > 3 cm after chemotherapy, for FDG-PET-CT an overall positive predictive value of only 23% and a false-positive rate of 77% [50]. In this study, PET results were correlated with histological examination of tissue samples obtained by biopsy or surgery. Thus, of 41 patients with histopathologic review, only 17% had viable seminoma, whereas necrosis was the most frequent finding of PET-positive lesions [50]. Although the majority of the current TGCT guidelines still recommend the use of FDG-PET-CT for postchemotherapeutic seminomas with residual tumors > 3 cm and a minimum 6–8 weeks interval postchemotherapy, the results of Cathomas et al. suggest, that a positive PET-CT scan should not be used as the only parameter for clinical decision making, due to reported high rate of false-positive results [5].

By contrast to seminomas, PET-CT has no role in evaluating the postchemotherapeutic masses of non-seminomas. A prospective trial on 121 patients found no advantage of PET-CT over conventional CT in the imaging of metastatic non-seminomas after chemotherapy [51]. The main reason for this inferior diagnostic performance of PET-CT in nonseminomatous residual tumors is probably the lacking uptake of the PET tracer in tissues with little or metabolic activity such as teratomas [47, 48]. Based on this results, the decision for surgical resection of residual tumors is presently based on conventional contrast-enhanced CT only, with a cut-off of 1 cm [5].

Possible improvements in hybrid imaging can either be made by substitution of CT by MRI or by the use of alternative tracers other than FDG. FDG-PET-MRI is an interesting option, that brings together the advantages of PET-based functional imaging with a high soft tissue contrast of MRI technique (Fig. 3/PET-MRT). To our knowledge, it has been investigated only on an individual patient level and study results are yet lacking because of the novelty of the technique.

In terms of new radiotracers, Gallium-68 labeled fibroblast activation protein inhibitor (Ga-68 FAPI), a positron emitter, plays a particular role. Tumor associated activated fibroblasts present a promising target for cancer imaging. An initial study has shown that that Ga-68 FAPI PET shows in comparison to FDG-PET a higher and rather selective
tracer uptake in 28 different tumor entities [52]. A phase 1 clinical trial NCT04459273 is underway to assess the role of Ga-68 FAPI PET/CT in several tumor entities including testicular cancers.

Another approach towards improved precision of solid tumor imaging is “radiomics”, an emerging field in radiology, which creates characteristic profiles of tumorous lesions by translating medical images into quantitative data. Recent developments have led to a stronger focus on machine learning and exploring new possibilities in artificial intelligence (AI) modeling [53]. Zheng et al. showed that AI algorithms demonstrated equivalent or even better performance compared to health-care professionals, in terms of sensitivity and specificity when used for the diagnosis of tumor metastasis [54].

Beassler et al. could show that a trained machine learning classifier was able to identify benign posttherapeutic changes in initially affected retroperitoneal lymph node metastases from NSTGCTs with a sensitivity, specificity and accuracy of 88%, 72% and 81%, respectively [55]. Similar results to predict pathology of postchemotherapeutic retroperitoneal lymph node metastases from NSTGCTs with a radiomics approach demonstrated Lewin et al. with a discriminative accuracy of 72% that improved to 88% when combined with clinical predictors [56].

**Conclusion**

Imaging is a cornerstone in TGCT management and has high relevance for the guidance of treatment decisions as well as the associated oncological outcomes. New ultrasound and MRI techniques are being introduced into the diagnostic armamentarium to improve the evaluation of unclear small testicular lesions and the clarification of borderline enlarged lymph nodes in patients with known TCGT. MRI should be preferred over CT for abdominal imaging in the follow-up of clinical stage I TGCTs, as it circumvents radiation exposure and recent studies have shown non-inferiority compared with CT. The judgment of postchemotherapeutic retroperitoneal residuals still relies mostly on conventional CT imaging and serum tumor markers, as the advantage of a FDG-PET-CT in this situation has limited benefits and new approaches incorporating radiomics have not yet entered clinical routine.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00345-021-03856-6.
Author contributions GW, FZ: conception, data collection, manuscript writing and editing. CR, AH, CB: manuscript editing. CL, VP: data collection, manuscript writing. KPD: manuscript writing and editing.

Funding Open Access funding enabled and organized by Projekt DEAL. GW received funding by the Ferdinand Eisenberger scholarship program (Funding number: WaG1/FE-20).

Data availability All figures and tables are available without restrictions.

Declarations

Conflict of interest VP has served on a scientific advisory board for POINT Biopharma (non-financial interest). All other authors have no conflicts of interest to declare that are relevant to the content of this article.

Human and animals rights All study protocols were in accordance with the principles of the 1964 Helsinki Declaration and its later amendments.

Informed consent No formal consent is required as our review does not include images that may identify the person and all personal identifiers were removed.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bray F, Richiardi L, Ekbom A et al (2006) Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 118:3099–3111. https://doi.org/10.1002/ijc.21747
2. Ruf CG, Isbarn H, Wagner W et al (2014) Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urol Oncol Semin Orig Investig 32:33.e1-33.e6. https://doi.org/10.1016/j.urolonc.2012.12.002
3. Cheng L, Albers P, Berney DM et al (2018) Testicular cancer. Nat Rev Dis Primer 4:29. https://doi.org/10.1038/s41572-018-0029-0
4. Winter C, Albers P (2011) Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 7:43–53. https://doi.org/10.1038/nrendo.2010.196
5. Laguna MP, Albers P, Algaba F, et al. (2021) EAU guidelines: testicular cancer. Amsterdam, The Netherlands 2021: EAU guidelines office 2021. https://uroweb.org/guideline/testicular-cancer/ISBN 978-94-92671-13-4. (Accessed 27 Apr 2021)
6. Rajpert-De Meyts E, McGlynn KA, Okamoto K et al (2016) Testicular germ cell tumours. Lancet Lond Engl 387:1762–1774. https://doi.org/10.1016/S0140-6736(15)00991-5
7. Dieckmann K-P, Richter-Simonsen H, Kulejewski M et al (2018) Testicular germ-cell tumours: a descriptive analysis of clinical characteristics at first presentation. Urol Int 100:409–419. https://doi.org/10.1159/000488284
8. Horwich A, Shipley J, Huddart R (2006) Testicular germ-cell cancer. Lancet Lond Engl 367:754–765. https://doi.org/10.1016/S0140-6736(06)68305-0
9. SEER Cancer Stat Facts: Testicular Cancer (2018) National Cancer Institute, Bethesda, MD. https://seer.cancer.gov/statfacts/html/testis.html. (Accessed Apr 27, 2021). In: SEER. https://seer.cancer.gov/statfacts/html/testis.html. (Accessed 27 Apr 2021)
10. Honecker F, Apricio J, Berney D, et al (2018) ESMO Consensus Conference on testicular germ cell cancer diagnosis treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 29:1658–1686. https://doi.org/10.1016/j.annonc.2017.04.007
11. Kiesch S, Schmidt S, Wilborn D et al (2021) Management of germ cell tumours of the testis in adult patients. german clinical practice guideline part i: epidemiology, classification, diagnosis, prognosis, fertility preservation, and treatment recommendations for localized stages. Urol Int 105:169–180. https://doi.org/10.1159/0005010407
12. Kiesch S, Schmidt S, Wilborn D et al (2021) Management of germ cell tumours of the testes in adult patients: german clinical practice guideline, PART II–recommendations for the treatment of advanced, recurrent, and refractory disease and extragonadal and sex cord/stromal tumours and for the management of follow-up, toxicity, quality of life, palliative care, and supportive therapy. Urol Int 105:181–191. https://doi.org/10.1159/0005011245
13. Sullivan CJ, Murphy KP, McLaughlin PD et al (2015) Radiation exposure from diagnostic imaging in young patients with testicular cancer. Eur Radiol 25:1005–1013. https://doi.org/10.1007/s00330-014-3507-0
14. Tarin TV, Geoffrey S, Rajesh S (2009) Estimating the risk of cancer associated with imaging related radiation during surveillance for stage i testicular cancer using computerized tomography. J Urol 181:627–633. https://doi.org/10.1016/j.juro.2008.10.005
15. Marko J, Wolfman DJ, Aubin AL, Sesterhenn IA (2017) Testicular seminoma and its mimics: from the radiologic pathology archives. Radiographics 37:1085–1098. https://doi.org/10.1148/rg.20171160164
16. Necas M, Muthupalanaiappan M, Barnard C (2021) Ultrasound morphological patterns of testicular tumours, correlation with histopathology. J Med Radiat Sci 68:21–27. https://doi.org/10.1002/jmrs.426
17. Toren PJ, Roberts M, Lecker I et al (2010) Small incidentally discovered testicular masses in infertile men—is active surveillance the new standard of care? J Urol 183:1373–1377. https://doi.org/10.1016/j.juro.2009.12.012
18. Paffenholz P, Held L, Loosen SH et al (2018) Testis sparing surgery for benign testicular masses: diagnostics and therapeutic approaches. J Urol 200:353–360. https://doi.org/10.1016/j.juro.2018.03.007
19. Isidori AM, Pozza C, Gianfrilli D et al (2014) Differential diagnosis of nonpalpable testicular lesions: qualitative and quantitative contrast-enhanced us of benign and malignant testicular tumors. Radiology 273:606–618. https://doi.org/10.1148/radiol.14132718
20. Giannarini G, Dieckmann K-P, Albers P et al (2010) Orang-sparing surgery for adult testicular tumours: a systematic review of the literature. Eur Urol 57:780–790. https://doi.org/10.1016/j.eururo.2010.01.014
21. Bieniek JM, Juvet T, Margolis M et al (2018) Prevalence and management of incidental small testicular masses discovered on ultrasonographic evaluation of male infertility. J Urol 199:481–486. https://doi.org/10.1016/j.juro.2017.08.004
22. Rocher L, Citron A, Gennisson J-L et al (2019) Characterization of testicular masses in adults: performance of combined
quantitative shear wave elastography and conventional ultrasound. Ultrasound Med Biol 45:720–731. https://doi.org/10.1016/j.ultrasoundmedbio.2018.10.027
23. Pedersen MR, Möller H, Østher PJS et al (2017) Comparison of tissue stiffness using shear wave elastography in men with normal testicular tissue, testicular microlithiasis and testicular cancer. Ultrasound Int Open 3:E150–E155. https://doi.org/10.1055/s-0043-116660
24. Sidhu PS, Cantisani V, Dietrich CF et al (2018) The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: Update 2017 (Long Version). Ultraschall Med Eur J Ultrasound 39:e2–e44. https://doi.org/10.1055/a-0586-1107
25. Tsili AC, Bertolotto M, Turgut AT et al (2018) MRI of the scrotum: recommendations of the ESUR scrotal and penile imaging working group. Eur Radiol 28:31–43. https://doi.org/10.1007/s00330-017-4944-3
26. Zhang P, Min X, Feng Z et al (2021) Value of intra-perinodal textural transition features from MRI in differentiating between benign and malignant testicular lesions. Cancer Manag Res 13:839–847. https://doi.org/10.2147/CMAR.S288378
27. Min X, Feng Z, Wang L et al (2018) Characterization of testicular germ cell tumors: whole-lesion histogram analysis of the apparent diffusion coefficient at 3T. Eur J Radiol 98:25–31. https://doi.org/10.1016/j.ejrad.2017.10.030
28. Zhang P, Feng Z, Cai W et al (2019) T2-weighted image-based radiomics signature for discriminating between seminomas and non-seminoma. Front Oncol. https://doi.org/10.3389/fonc.2019.01330
29. Feliciani G, Mellini L, Carnevale A et al (2021) The potential role of MR based radiomic biomarkers in the characterization of focal testicular lesions. Sci Rep. https://doi.org/10.1038/s41598-021-83023-4
30. Tsili AC, Ntorkou A, Astrakas L et al (2017) Diffusion-weighted magnetic resonance imaging in early stage testicular cancer: what the radiologist needs to know. Am J Roentgenol 209:1215–1225. https://doi.org/10.2214/AJR.17.10319
31. Pierorazio PM, Cheaib JG, Toma G et al (2020) Performance characteristics of clinical staging modalities for early stage testicular germ cell tumors: a systematic review. J Urol 203:894–901. https://doi.org/10.1097/JU.00000000000020594
32. Kreydin EI, Barrisford GW, Feldman AS, Preston MA (2013) Testicular cancer: what the radiologist needs to know. Am J Roentgenol 200:1215–1225. https://doi.org/10.2214/AJR.12.10319
33. Forsberg L, Dale L, Høiem L et al (1986) Computed tomography in early stages of testicular carcinoma. Size of normal retroperitoneal lymph nodes and lymph nodes in patients with metastases in stage II A. A SWENOTECA study: Swedish-Norwegian testicular cancer project. Acta Radiol Diagn (Stockh) 27:569–574. https://doi.org/10.1177/028248518602700516
34. Hilton S, Herr HW, Teitcher JB et al (1997) CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 169:521–525. https://doi.org/10.2214/ajr.169.2.9242768
35. Sohaib SA, Koh DM, Barbachano Y et al (2009) Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol 64:362–367. https://doi.org/10.1016/j.crad.2008.10.011
36. Joffe JK, Cafferty FH, Murphy L et al (2021) Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: results from a randomized, phase III, factorial trial (TRISSST). J Clin Oncol 39:374–374. https://doi.org/10.1200/JCO.2021.39.6_suppl.374
37. Laukka M, Mannisto S, Beule A et al (2020) Comparison between CT and MRI in detection of metastasis of the retroperitoneum in testicular germ cell tumors: a prospective trial. Acta Oncol 59:660–665. https://doi.org/10.1080/0284186X.2020.1725243
38. Larsen SKA, Agerbak M, Jurik AG, Pedersen EM (2020) Ten years of experience with MRI follow-up of testicular cancer stage I: a retrospective study and an MRI protocol with DWI. Acta Oncol 59:1374–1381. https://doi.org/10.1080/0284186X.2020.1794035
39. de Wit M, Brenner W, Hartmann M et al (2008) [(18)F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol Off J Eur Soc Med Oncol 19:1619–1623. https://doi.org/10.1093/annonc/mdn170
40. Harisinghani MG, Saksena M, Ross RW et al (2005) A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology 66:1066–1071. https://doi.org/10.1016/j.urology.2005.05.049
41. Larsen SKA (2020) Whole body MRI with DWI for monitoring patients treated for testicular cancer stage II–III ; https://clinicaltrials.gov
42. Mosavi F, Laurell A, Ahlström H (2015) Whole body MRI, including diffusion-weighted imaging in follow-up of patients with testicular cancer. Acta Oncol 54:1763–1769. https://doi.org/10.3109/0284186X.2015.1043027
43. Ambrosini V, Zucchini G, Nicolisi S et al (2014) 18F-FDG PET/CT impact on testicular tumours clinical management. Eur J Nucl Med Mol Imaging 41:668–673. https://doi.org/10.1007/s00259-013-2624-3
44. Hain SF, O’Doherty MJ, Timothy AR et al (2000) Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 27:590–594. https://doi.org/10.1007/s00259-980050547
45. Albers P, Bender H, Yilmaz H et al (1999) Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell cancer. Urology 53:808–811. https://doi.org/10.1016/S0090-4295(98)00576-7
46. Li Y, Jiang L, Wang H et al (2019) Effective radiation dose of 18F-FDG PET/CT: how much does diagnostic CT contribute? Radiat Prot Dosimetry 187:183–190. https://doi.org/10.1093/rpd/ncz153
47. Daneshmand S, Albers P, Fossa SD et al (2012) Contemporary management of postchemotherapy testis cancer. Eur Urol 62:867–876. https://doi.org/10.1016/j.eururo.2012.08.014
48. Pfannenberg AC, Oechsle K, Bokemeyer C et al (2004) The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors–prospects for management. World J Urol 22:132–139. https://doi.org/10.1007/s00259-003-0392-6
49. Bachner M, Lorioy Y, Gross-Goupil M et al (2012) 2–18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPELT trial. Ann Oncol 23:59–64. https://doi.org/10.1093/annonc/mdr052
50. Catbas H, Kliingbiel D, Bernard B et al (2018) Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an international global germ cell cancer group registry. J Clin Oncol 36:3381–3387. https://doi.org/10.1200/JCO.2018.00210
51. Oechsle K, Hartmann M, Brenner W et al (2008) [(18)F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol Off J Am Soc Clin Oncol 26:5930–5935. https://doi.org/10.1200/JCO.2008.17.1157

Springer
52. Kratochwil C, Flechsig P, Lindner T et al (2019) 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60:801–805. https://doi.org/10.2967/jnumed.119.227967

53. Rogers W, Thulasi Seetha S, Refaee TAG et al (2020) Radiomics: from qualitative to quantitative imaging. Br J Radiol. https://doi.org/10.1259/bjr.20190948

54. Zheng Q, Yang L, Zeng B et al (2020) Artificial intelligence performance in detecting tumor metastasis from medical radiology imaging: a systematic review and meta-analysis. EClinical Medicine. https://doi.org/10.1016/j.eclinm.2020.100669

55. Baessler B, Nestler T, Pinto Dos Santos D et al (2020) Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection. Eur Radiol 30:2334–2345. https://doi.org/10.1007/s00330-019-06495-z

56. Lewin J, Dufort P, Halankar J et al (2018) Applying radiomics to predict pathology of postchemotherapy retroperitoneal nodal masses in germ cell tumors. JCO Clin Cancer Inform. https://doi.org/10.1200/CCI.18.00004

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.